Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer

 Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer

Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer

Shots:

  • Seattle Genetics and Astellas sign a clinical trial agreement with Merck to evaluate the combination of Seattle Genetics’ and Astellas’ ADC and Merck’s anti-PD-1 therapy in patients with previously untreated metastatic urothelial cancer
  • The three companies will conduct and fund P-III study to be led by Seattle Genetics and will work with regulatory authorities to finalize the trial design with the expected onset of the study in H1’20
  • Enfortumab Vedotin is an investigational ADC comprising of an anti-Nectin-4 mAb, attached to a MMAE utilizing Seattle Genetics’ technology and has received FDA’s BT designation in Mar’2018 with its PDUFA date as Mar 15, 2020

Click here to­ read full press release/ article | Ref: Astellas | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post